This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
31 Jul 2020

NEW CE CERTIFICATIONS FOR THREE NTC PRODUCTS BASED ON TIAB TECHNOLOGY

NTC Srl, R&D focused pharmaceutical company headquartered in Italy, has obtained CE certifications for three medical devices based on TIAB technology: a new vaginal gel GENIGEL, a proctological cream-gel TIAHEM and a powder for wound care TIAHEL.

Milan, 22 July 2020 – NTC Srl, R&D focused pharmaceutical company headquartered in Italy, has obtained CE certifications for three medical devices based on TIAB technology: a new vaginal gel GENIGEL, a proctological cream-gel TIAHEM and a powder for wound care TIAHEL.

These are three new entries in the innovative NTC list of products “ready for partnering now”. This achievement is part of the NTC commitment in embracing new therapeutic approaches exploiting innovative formulations such as its patented TiAB & SiAB technologies.

TiAb and SiAB are made of micro-particles, based on titanium and silica dioxide respectively, designed to enhance the activity of silver ions (Ag+).

“NTC keeps developing new therapeutic solutions using the TiAb and SiAB technologies and keeps offering to its Partners globally new innovative medical devices” Riccardo Carbucicchio, Chairman and CEO of NTC, states. “During the last few years we have been working relentlessly, efficiently and swiftly, even during the lockdown due to COVID-19 emergency, and we managed to obtain EU certification in gynaecology for GENIGEL, in proctology for TIAHEM and in wound healing for TIAHEL. We are excited now to partner and to license-out these new products in Europe and in the rest of World”.

Mentioned Companies
NTC S.r.l.
View company profile